SCHEMBL6525007

SCHEMBL6525007

Fc1ccccc1Oc1ccc2c(Cl)nc3ncccc3c2c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
HCAR2 Q8TDS4 4/20 0.41
GCK P35557 2/20 0.40
TRPA1 O75762 2/20 0.36
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
F7 P08709 1/20 0.36
F3 P13726 1/20 0.36
EGFR P00533 1/20 0.35
ALDH1A1 P00352 2/20 0.35
ESR1 P03372 1/20 0.35
PARP10 Q53GL7 1/20 0.35
MAPK1 P28482 1/20 0.34
HTR1A P08908 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
PIN1 Q13526 1/20 0.34
HCAR3 P49019 1/20 0.34
MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520629 0.81 HCAR2 (0.45) KDM4EHCAR2ALDH1A1
SCHEMBL3454517 0.81 HCAR2 (0.43) KDM4EHCAR2ALDH1A1MAPK1
SCHEMBL6523544 0.79 HCAR2 (0.46) HCAR2EGFR
SCHEMBL3453991 0.79 RAB9A (0.41) HCAR2ALDH1A1
SCHEMBL3453868 0.77 ABCG2 (0.44)
SCHEMBL6517522 0.76 CYP19A1 (0.44) KDM4EHCAR2GCK
SCHEMBL3454218 0.76 BCHE (0.41) KDM4ETRPA1ALDH1A1MAPK1
SCHEMBL12786615 0.73 MAPT (0.48) KDM4EHCAR2F2F10F7
SCHEMBL6524942 0.72 IDO1 (0.45) HCAR2ALDH1A1MAPK1
SCHEMBL3454618 0.72 AURKA (0.56) KDM4EHCAR2GCKPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 KDM4E 1872/4885HCAR2 4241/4885GCK 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.